For millions of people who take GLP-1 drugs like Wegovy and Zepbound, the experience can feel like it changes their lives. After years of trying, appetite often goes down a lot, cravings go away, and long-term weight loss becomes possible. (Source)
However, there is one constant exception found in clinical trials: around 10%-15% of individuals do not lose significant amounts of weight despite taking the medication according to instructions. The term "non-responder" refers increasingly often to such patients in terms of weight loss. The increasing scientific data prove that GLP-1 medications may remain effective regardless of weight loss or gain.
The "Non-Responder" Hypothesis in GLP-1 Treatment
Two examples of GLP-1 receptor agonists include semaglutide (Wegovy) and tirzepatide (Zepbound). The first objective of using them was regulating blood glucose levels and appetite through stimulation of the gut-brain axis.
However, not all patients respond in the same way to GLP-1 medication treatment. During the trials:
Some participants experienced minimal weight loss, if any.
Others demonstrated metabolic benefits while keeping their body weight constant.
Such differences might appear because of the genetic makeup of particular patients.
The latest studies even suggested that it is the genetic make-up which might determine why some people do not respond to GLP-1 treatment.
New Evidence: Benefits Without Weight Loss
Until recently, weight reduction was the key indicator of effectiveness. However, new studies suggest otherwise.
For instance, scientists started to understand that GLP-1 receptor agonists are able to produce beneficial effects on patients independently of whether weight loss is achieved, in:
1. Health of the heart
Clinical trials have demonstrated a diminished risk of:
Heart attacks
Stroke
Problems that come with heart failure
Importantly, these benefits have been noted even in participants who did not experience substantial weight loss, indicating additional biological mechanisms beyond mere fat reduction.
Liver Disease (MASH)
The FDA's recent approval of semaglutide (Wegovy) for treating metabolic dysfunction-associated steatohepatitis (MASH) is one of the most important recent events. MASH is a serious liver disease that affects millions of adults in the U.S.
In clinical trials, patients had:
Big changes in the markers of liver inflammation
In some cases, the disease gets better.
Benefits not entirely elucidated by weight reduction alone.
Researchers now think that GLP-1s may have an effect on immune and vascular pathways in the liver.
How GLP-1 Drugs Might Work Even If You Don't Lose Weight
Scientists are finding ways that go beyond just making people less hungry.
Researchers have seen in experimental studies that GLP-1 drugs may:
Lower inflammation in liver tissue
Engage with uncommon populations of blood vessel cells
Signal changes in the immune system that help with metabolic stress
One research team even made animal models that didn't lose weight when they were on GLP-1 therapy. Even so, they still saw improvements in liver health markers, which suggests that there was a direct biological effect that didn't depend on weight change.
In subsequent experiments, the elimination of the pertinent liver-cell signaling pathway resulted in the cessation of those benefits, thereby reinforcing the hypothesis of a direct mechanism.
Inflammation: An Important Link Between Diseases
A new idea is that GLP-1 drugs work in part by lowering inflammation throughout the body.
This could be why benefits are being seen in a number of different conditions:
Lowering the risk of heart disease
Improvements in kidney disease
Slowing down the progression of liver disease
Some cardiology studies have shown that losing weight does not have a strong effect on lowering the risk of heart attacks and strokes. Instead, betterments in:
Control of blood sugar
Pressure in the blood
Inflammatory markers could be very important.
Rethinking What "Success" Means in Weight-Loss Prescriptions
At the moment, a lot of insurance companies want patients to show that they have lost at least 5% of their body weight in a few months in order to keep getting GLP-1 medications.
However, doctors say that this standard may no longer show the full therapeutic value of these drugs.
Experts now say that:
Patients may see metabolic benefits even if their weight doesn't change.
Weight alone may be an inadequate metric for assessing response.
Coverage decisions should take into account a wider range of health outcomes.
This could have a big effect on insurance policies and how easy it is to get treatment in the long term.
Constraints of Existing Research
The researchers point out that a considerable number of mechanistic data have been collected by animal experiments, despite the promising results.
Animal models can provide a pathway to finding biologically-based pathways, although it is yet unclear whether the same events take place in humans as well.
There are still several unresolved issues:
Why do certain patients receiving GLP-1 preparations fail to lose weight?
What role is played by GLP-1's direct effect on certain organs?
Is a differentiated strategy regarding dosing necessary when it comes to achieving metabolic or weight-related objectives?
A Possible Paradigm Shift
With more knowledge gained, some scientists believe that individualization of therapy based on GLP-1 may become necessary:
Small doses for patients with liver diseases
High doses for obesity treatment
Individual objectives going beyond BMI decrease
Thus, one will be able to avoid side effects such as nausea and abdominal discomfort.
Final Thoughts
This new science regarding GLP-1 drugs has caused a major shift in perception of their benefits. Weight reduction remains one of the most popular advantages offered by these medicines, although it now appears that there are other benefits associated with these treatments as well.
Even in cases where patients do not lose weight, it seems likely that they would have experienced enough protection from diseases like cardiovascular disease and liver problems to suggest that the medical implications extend further than previously thought.
A change to what it means to be successful with GLP-1 therapy might be needed soon.
